Production & Sales

Alkermes launches award program for research on CNS disorders

Alkermes has launched a new competitive awards program called the ALKERMES Pathways Research Awards Program to support the next generation of researchers working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders.

Endo to buy Somerset Therapeutics for $190m

Endo International has agreed to acquire New Jersey-based Somerset Therapeutics, that develops and markets sterile injectable and ophthalmic drugs, and the business of its India-based affiliate Wintac, which operates as Somerset's contract developer and manufacturer.

Shire considers Takeda’s revised £46bn takeover offer

Shire’s board said that it is willing to recommend Takeda Pharmaceutical’s revised acquisition offer of £46bn to its shareholders.

Synpromics to partner with Lonza to improve biopharmaceuticals manufacturing

Synpromics has partnered with Lonza Pharma & Biotech to further develop its inducible promoter system and enhance manufacturing of biopharmaceuticals.

Fresenius Kabi scraps $4.3bn merger with US generic drugmaker Akorn

Germany-based Fresenius Kabi has scrapped its $4.3bn merger agreement with Akorn, saying that the US generic drugmaker did not fulfill various closing conditions.

Merck to sell global consumer health business to P&G for $4.2bn

Merck has agreed to sell its global consumer health business to Procter & Gamble (P&G) for about €3.4bn ($4.2bn).

Advent in talks to buy Sanofi’s European generics business for EUR1.9bn

US-based global private equity firm Advent International has entered into exclusive talks to acquire Sanofi’s European generics business, Zentiva, for €1.9bn.

Servier to buy Shire’s oncology business for $2.4bn

French pharmaceutical firm Servier has signed an agreement to acquire the oncology business of Shire for $2.4bn.

Helsinn to acquire global rights of Valchlor/Ledaga from Actelion Pharmaceuticals

Helsinn has agreed to acquire worldwide rights to Valchlor/Ledaga (mechlorethamine/chlormethine), an alkylating agent for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), from Actelion Pharmaceuticals.